50 µg

DYKDDDDK Epitope Tag Synthetic Peptide, PEP-087, from Invitrogen.

nDYKDDDDK Tag (FLAG-tag, FLAG octapeptide) is a polypeptide protein tag that can be added to a protein using recombinant DNA technology. The FLAG tag structure has been optimized for compatibility with the proteins it is attached to, in that it is more hydrophilic than other common epitope tags and therefore less likely to denature or inactivate proteins to which it is appended. A FLAG-tag can be used in many different assays that require recognition by an antibody. If there is no antibody against the studied protein, adding a FLAG-tag to this protein allows one to follow the protein with an antibody against the FLAG sequence. Examples are cellular localization studies by immunofluorescence or detection by SDS PAGE protein electrophoresis. Tagging with xxxDDDDK may be done at the N-terminus, N-terminus preceded by a methionine residue, C-terminus, and in internal positions of the target protein. The small size of the epitope tag and its high hydrophilicity tend to decrease the possibility of interference with protein expression, proteolytic maturation, antigenicity and function. The enterokinase cleavage site allows it to be completely removed from the purified fusion proteins. similar epitope as the FLAG tag from SigmaThis peptide may be used for neutralization and control experiments with the polyclonal antibody that reacts with this product (Product &Num; PA1-984B) and fusion proteins containing the epitope tag DYKDDDDK. Using a solution of peptide of equal volume and concentration to the corresponding antibody will yield a large molar excess of peptide (?70-fold) for competitive inhibition of antibody-protein binding reactions.Reconstitute with 0.1 mL of distilled water.

CTRP5 Synthetic Peptide, PEP-0003, from Invitrogen.

nThis peptide corresponds to 15 amino acids near the center of human CTRP5PEP-0003 can be used as a blocking peptide with polyclonal antibody PA5-20153.

DR5 Synthetic Peptide, PEP-0021, from Invitrogen.

nDR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome. This peptide corresponds to 20 amino acids near the carboxy terminus of human DR5.PEP-0021 can be used as a blocking peptide with polyclonal antibody PA5-19895.

ITI-HC1 Synthetic Peptide, PEP-301, from Invitrogen™.

nThe inter-alpha-trypsin inhibitors (ITI) are a family of structurally related plasma serine protease inhibitors involved in extracellular matrix stabilization and in prevention of tumor metastasis. The ITI family contains multiple proteins made up of a light chain (see MIM 176870) and a variable number of heavy chains (Salier et al., 1987 [PubMed 2446322]; Himmelfarb et al., 2004 [PubMed 14744536]). This peptide corresponds to amino acids Q(383) VQESLPELSN (393) of human ITI-HC1 and can be used as a blocking peptide with polyclonal antibody PA1-1755.

Recombinant Protein